1Ridker PM,Rifai N,Pfeffer MA,et al.Long-term effects of pravastatin on plasma concentration of C-reactive protein:The Cholesterol and Recurrent Events (CARE) Investigators[J].Circulation,1999,100:230-235.
2Sager PT,Melani L,Lipka L,et al.Effect of coadministration of ezetimibe and simvastatin on high-sensitivity C-reactive protein[J].Am J Cardiol,2003,92:1414-1418.
3Wilson TM,Cobb JE,Cowan DJ,et al.The structure activity relationship between perxisome proliferators-activated receptor against and the antihyperglycemic activity of thiazolidine[J].J Med Chem,1996,39(3):665.
4Saftiel AR,Oefsky JM.Thiaxolidinediones in the treatment of insulin resistance and type Ⅱ diabetes[J].Diabetes,1996,45(12):1661.
5Pearson TA,Mensah GA,Alexander RW,et al.American Heart Associationguide for improving cardiovascular health at the community level:A statementfor public health practitioners,healthcare providers and health policy makersfrom the American Heart Association Expert Panel on Population and Preven-tion Science[J].Circulation,2003,107:645-651.
6Ridker PM,Rifai N,Lynda R,et al.Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events[J].N Engl J Med,2002,347:1557-1565.
7Ridker PM,Buring JE,Cook NR,et al.C-reactive protein,the metabolic syndrome and risk of incident cardiovascular events[J].Circulation,2003,107:391-397.
9Blake GJ,Otvos JD,Rifai N,et al.Low-density lipoprotein particle concentration and size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular disease in women[J].Circulation,2002,106:1930-1937.
10Expert Panel on Detection,Evaluation,and Treatment of High Blood Cholesterol in Adults.Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection,Evaluation,and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel Ⅲ)[J].JAMA,2001,285:2486-2497.
